GenFleet Therapeutics is a clinical-stage biotechnology company based in Shanghai focused on developing cutting-edge therapies in oncology and immunology. The company has a proprietary R&D and discovery platform and is developing both small molecules and biologics. Its diversified pipeline includes over 10 products, many of which have progressed into clinical stages. GenFleet is expanding clinical trials in China, the United States and Australia and expects more programs to move into late-stage clinical development in 2022. Management says proceeds will support global development of clinical-stage programs, build a broader portfolio of innovative programs, and accelerate commercialization over the coming years. GenFleet Therapeutics develops new drug candidates and is stepping into global multi-center clinical trials. The company announced a Series B+ financing in the hundreds of millions of RMB to speed development of its existing products and the conduct of its clinical trials. It plans to create an international cutting‑edge R&D system and open its industrial layout in parallel. Proceeds will be used to continually complete milestones of its "global new" drug development. The financing marks a new development stage focused on accelerating clinical programs and building international capabilities. DeHeng Law Offices acted as legal counsel on the transaction. GenFleet Therapeutics develops small-molecule therapeutics for immuno-oncology. The company’s first product entered IND application stage just over one year after the program was launched. Proceeds from its latest financing are intended to advance the IND application and subsequent clinical development of that program. GenFleet says it is executing projects rapidly and expanding its pipeline and business functions. Leadership has stated the company aims to become a pioneer in immuno-oncology and to build an innovative, balanced product portfolio to address unmet needs. The company is based in Shanghai, China.

Total raised

$96M

Funding rounds

3

Latest round

Series C

Latest activity

Jan 2022